• Explore /
  • Poster
  • / Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

Abstract Poster

Authors

null

Roy S. Herbst

Yale University School of Medicine, New Haven, CT

Roy S. Herbst , Ian Chau , Daniel Peter Petrylak , Hendrik-Tobias Arkenau , Johanna C. Bendell , Rafael Santana-Davila , Emiliano Calvo , Nicolas Penel , Juan Martin-Liberal , Andres O. Soriano , Philippe Alexandre Cassier , Matthew Krebs , Nicolas Isambert Sr., Ryan Widau , Gu Mi , Jin Jin , David Raymond Ferry , Charles S. Fuchs , Luis G. Paz-Ares

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02443324

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3059)

DOI

10.1200/JCO.2018.36.15_suppl.3059

Abstract #

3059

Poster Bd #

273

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Ian Chau

First Author: Roy S. Herbst

First Author: Biagio Ricciuti